DK2657234T3 - Optisk aktivt diazabicyclooctanderivat og fremgangsmåde til fremstilling heraf - Google Patents

Optisk aktivt diazabicyclooctanderivat og fremgangsmåde til fremstilling heraf Download PDF

Info

Publication number
DK2657234T3
DK2657234T3 DK11850585.8T DK11850585T DK2657234T3 DK 2657234 T3 DK2657234 T3 DK 2657234T3 DK 11850585 T DK11850585 T DK 11850585T DK 2657234 T3 DK2657234 T3 DK 2657234T3
Authority
DK
Denmark
Prior art keywords
preparation
optically active
diazabicyclooctane derivative
active diazabicyclooctane
derivative
Prior art date
Application number
DK11850585.8T
Other languages
English (en)
Inventor
Takao Abe
Masayuki Okue
Yoshiaki Sakamaki
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Application granted granted Critical
Publication of DK2657234T3 publication Critical patent/DK2657234T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK11850585.8T 2010-12-22 2011-06-30 Optisk aktivt diazabicyclooctanderivat og fremgangsmåde til fremstilling heraf DK2657234T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010073093 2010-12-22
PCT/JP2011/065001 WO2012086241A1 (ja) 2010-12-22 2011-06-30 光学活性なジアザビシクロオクタン誘導体およびその製造法

Publications (1)

Publication Number Publication Date
DK2657234T3 true DK2657234T3 (da) 2017-02-20

Family

ID=46313528

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11850585.8T DK2657234T3 (da) 2010-12-22 2011-06-30 Optisk aktivt diazabicyclooctanderivat og fremgangsmåde til fremstilling heraf

Country Status (18)

Country Link
EP (1) EP2657234B1 (da)
JP (3) JP5903386B2 (da)
KR (1) KR101836554B1 (da)
CN (2) CN103328476B (da)
AR (1) AR116907A2 (da)
AU (2) AU2011346224B2 (da)
CA (1) CA2822758C (da)
DK (1) DK2657234T3 (da)
ES (1) ES2622004T3 (da)
HK (1) HK1210153A1 (da)
HU (1) HUE032491T2 (da)
IL (5) IL227087A0 (da)
PL (1) PL2657234T3 (da)
RU (1) RU2591701C2 (da)
SG (2) SG10201510576WA (da)
SI (1) SI2657234T1 (da)
TW (1) TWI599355B (da)
WO (1) WO2012086241A1 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2622004T3 (es) * 2010-12-22 2017-07-05 Meiji Seika Pharma Co., Ltd. Derivado de diazabiciclooctano ópticamente activo y método para preparar el mismo
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
US8829191B2 (en) * 2011-06-17 2014-09-09 Melanie Simone Ronsheim Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8962843B2 (en) 2012-03-30 2015-02-24 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
JP2015512419A (ja) 2012-03-30 2015-04-27 キュービスト ファーマシューティカルズ, インコーポレイテッド イソオキザゾールβ−ラクタマーゼ阻害剤
WO2013180197A1 (ja) 2012-05-30 2013-12-05 Meiji Seikaファルマ株式会社 新規β-ラクタマーゼ阻害剤とその製造法
EP2915805A4 (en) * 2012-11-01 2016-03-23 Kaneka Corp METHOD FOR PRODUCING AN OPTICALLY ACTIVE BICYCLIC UREA COMPOUND
BR112015021332B1 (pt) * 2013-03-08 2020-06-30 Wockhardt Limited sal de sódio de ácido (2s, 5r)-6-benzilóxi-7-oxo-1,6-diaza-biciclo [3.2.1] octano-2-carboxílico e sua preparação
WO2014135931A1 (en) * 2013-03-08 2014-09-12 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo [3.2.1]- octane
CN108191864A (zh) * 2013-03-08 2018-06-22 沃克哈特有限公司 制备氧代磺酰氧基[(哌啶羰基)-肼基羰基]二氮杂-双环辛烷的方法
WO2014135930A1 (en) * 2013-03-08 2014-09-12 Wockhardt Limited A process for sodium salt of (2s, 5r)-2-carboxamido-7-oxo-6-sulfooxy -1,6-diaza-bicyclo[3.2.1]octane
WO2014135932A1 (en) 2013-03-08 2014-09-12 Wockhardt Limited A process for preparation of (2s, 5r)-7-oxo-6-sulphooxy-2-[((3r)-pyrrolidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane
CA2904084C (en) * 2013-03-08 2017-03-28 Wockhardt Limited A process for preparation of (2s, 5r)- sulfuric acid mono-{[(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
DK3050883T3 (da) * 2013-09-24 2020-05-25 Meiji Seika Pharma Co Ltd Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
ES2901198T3 (es) 2013-10-08 2022-03-21 Meiji Seika Pharma Co Ltd Formas cristalinas de derivado de diazabiciclooctano y procedimiento de producción de las mismas
WO2015114595A1 (en) * 2014-02-03 2015-08-06 Wockhardt Limited A process for preparation of (2s, 5r)-1,6-diaza-bicyclo [3.2.1]octane-2-carbonitrile-7-oxo-6-(sulfooxy)-mono sodium salt
EP3126363A1 (en) 2014-03-29 2017-02-08 Wockhardt Limited A process for preparation of sodium (2s, 5r)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate
RU2732129C2 (ru) 2014-12-05 2020-09-11 Мейдзи Сейка Фарма Ко., Лтд. Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированного препарата
PT3334734T (pt) * 2015-08-10 2020-04-06 Sandoz Ag Forma c de avibactam sódico
CN107325096B (zh) * 2016-04-29 2020-11-03 正大天晴药业集团股份有限公司 一种阿维巴坦单钠盐的结晶
CN106565712A (zh) * 2016-09-30 2017-04-19 天津津泰生物医药技术有限公司 一种阿维巴坦钠中间体的制备方法
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
CN106866668B (zh) * 2017-01-23 2019-01-11 齐鲁天和惠世制药有限公司 一锅法制备阿维巴坦钠的方法
CN106831772B (zh) * 2017-03-04 2019-12-17 丽珠医药集团股份有限公司 一种阿维巴坦中间体的合成方法
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2018234962A1 (en) * 2017-06-20 2018-12-27 Wockhardt Limited PROCESS FOR O-SULFONATION OF 1,6-DIAZABICYCLO [3.2.1] OCTANE COMPOUNDS
CN109400521B (zh) * 2017-08-18 2020-05-08 新发药业有限公司 一种改进的5r-苄氧氨基哌啶-2s-甲酸酯、其草酸盐的制备方法
CN107417686B (zh) * 2017-09-19 2020-04-28 北京化工大学 一种阿维巴坦钠的合成方法
MX2020004071A (es) 2017-10-02 2020-07-28 Arixa Pharmaceuticals Inc Derivados de aztreonam y usos de los mismos.
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
CN109678855B (zh) 2017-10-18 2020-07-17 新发药业有限公司 一种阿维巴坦中间体的制备方法
TWI826399B (zh) 2017-11-03 2023-12-21 瑞士商愛爾康公司 氮雜雙環和二氮呯衍生物
CN107907604B (zh) * 2017-11-07 2021-01-22 中山奕安泰医药科技有限公司 (2s,5r)-苯氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
CN107941969B (zh) * 2017-11-07 2021-03-02 中山奕安泰医药科技有限公司 (2s,5r)-苯氧胺基哌啶-2-甲酰胺的检测方法
CN107894471A (zh) * 2017-11-07 2018-04-10 中山奕安泰医药科技有限公司 一种阿维巴坦钠中间体的检测方法
TW201925201A (zh) * 2017-11-10 2019-07-01 日商鹽野義製藥股份有限公司 二氮雜二環辛烷衍生物
CN107941944B (zh) * 2017-11-23 2020-09-15 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
US11180501B2 (en) 2017-12-01 2021-11-23 Qilu Pharmaceutical Co., Ltd. Crystal form of β-lactamase inhibitor and preparation method therefor
CN109956941B (zh) 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
CN109970625B (zh) * 2017-12-28 2021-02-26 新发药业有限公司 一种5r-苄氧氨基哌啶-2s-甲酸或其衍生物的制备方法
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11897844B2 (en) * 2018-09-21 2024-02-13 Api Corporation Method for producing amino acid derivatives
US11180500B2 (en) 2018-10-01 2021-11-23 Arixa Pharmaceuticals, Inc. Derivatives of relebactam and uses thereof
US11008321B2 (en) 2019-03-12 2021-05-18 Arixa Pharmaceuticals, Inc. Crystalline form of an avibactam derivative
WO2020219258A1 (en) 2019-04-25 2020-10-29 Arixa Pharmaceuticals, Inc. Methods of synthesizing aztreonam derivatives
CN111777607A (zh) * 2020-07-21 2020-10-16 海南海灵化学制药有限公司 一种阿维巴坦纳的制备方法
CN116375706A (zh) * 2023-02-22 2023-07-04 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737194B1 (en) * 1993-12-29 1999-03-03 Pfizer Inc. Diazabicyclic neurokinin antagonists
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
PT2666774E (pt) * 2008-01-18 2015-04-13 Merck Sharp & Dohme Inibidores de beta-lactamase
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2921559A1 (en) * 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
ES2622004T3 (es) * 2010-12-22 2017-07-05 Meiji Seika Pharma Co., Ltd. Derivado de diazabiciclooctano ópticamente activo y método para preparar el mismo

Also Published As

Publication number Publication date
CA2822758A1 (en) 2012-06-28
CN104892490A (zh) 2015-09-09
SG10201510576WA (en) 2016-01-28
CN103328476A (zh) 2013-09-25
IL243939A0 (en) 2016-04-21
IL227087A0 (en) 2016-10-31
JP5903386B2 (ja) 2016-04-13
IL248246A0 (en) 2016-11-30
AU2011346224B2 (en) 2017-04-06
JP2018009008A (ja) 2018-01-18
AR116907A2 (es) 2021-06-23
IL244239A0 (en) 2016-04-21
CA2822758C (en) 2018-03-20
PL2657234T3 (pl) 2017-06-30
JP2016117742A (ja) 2016-06-30
RU2591701C2 (ru) 2016-07-20
JPWO2012086241A1 (ja) 2014-05-22
AU2017203187A1 (en) 2017-06-01
HUE032491T2 (en) 2017-09-28
EP2657234A1 (en) 2013-10-30
EP2657234B1 (en) 2017-01-11
WO2012086241A1 (ja) 2012-06-28
AU2011346224A1 (en) 2013-07-04
KR20140040688A (ko) 2014-04-03
RU2013133870A (ru) 2015-01-27
EP2657234A4 (en) 2014-10-08
ES2622004T3 (es) 2017-07-05
IL248246B (en) 2021-02-28
JP6364431B2 (ja) 2018-07-25
HK1210153A1 (en) 2016-04-15
AU2017203187B2 (en) 2018-07-26
SG191320A1 (en) 2013-07-31
TWI599355B (zh) 2017-09-21
TW201225958A (en) 2012-07-01
KR101836554B1 (ko) 2018-04-19
IL244239B (en) 2019-01-31
IL238032A (en) 2017-05-29
CN104892490B (zh) 2017-07-21
SI2657234T1 (sl) 2017-06-30
CN103328476B (zh) 2016-12-28

Similar Documents

Publication Publication Date Title
DK2657234T3 (da) Optisk aktivt diazabicyclooctanderivat og fremgangsmåde til fremstilling heraf
DK3622883T3 (da) Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger
DK3260457T3 (da) Fremgangsmåde til at fremstille carbamoylpyridonderivater og -mellemprodukter
DK3045187T3 (da) Injektor og fremgangsmåde til samling
DK2857401T3 (da) Hidtil ukendt -lactamaseinhibitor og fremgangsmåde til at fremstille samme
DK2675827T3 (da) Hidtil ukendte modulatorer og fremgangsmåder til anvendelse
DK3468197T3 (da) Fremgangsmåde til interforudsigelse og indretning dertil
DK3327040T3 (da) Multimeriske opløselige il-15-fusionsmolekyler og fremgangsmåder til at fremstille og anvende samme
DK2602089T3 (da) Resinform til nanotryk og fremgangsmåde til fremstilling deraf
DK2635337T3 (da) Pakke med kateter og fremgangsmåde til sterilisering deraf
DK2632954T4 (da) Midler og fremgangsmåder til behandling af dlbcl
DK3263100T3 (da) L-ornithinphenylacetat og fremgangsmåder til fremstilling deraf
DK2408807T3 (da) Fremgangsmåde til terapeutisk anvendelse
DK2758349T3 (da) Vanadiumbaserede frittematerialer og fremgangsmåder til fremstilling heraf
DK3156075T3 (da) Oligosaccharid og fremgangsmåde til fremstilling deraf
DK2584921T3 (da) Sondeernæringspakninger og fremgangsmåder til anvendelse deraf
DK2596099T3 (da) Fremgangsmåde til høst af ekspressionsprodukter
DK2771022T3 (da) Cd40l-specifikke tn3-afledte skeletter (scaffolds) og fremgangsmåder til anvendelse deraf
DK2600715T3 (da) Flydende ST-246-formuleringer og fremgangsmåder
NO345087B1 (no) System og fremgangsmåte for forspenning av stigerør
BRPI1005433A2 (pt) preparações farmacêuticas transdérmicas
DK2908661T3 (da) Mikroalgemelgranulater og fremgangsmåde til fremstilling deraf
DK2544986T3 (da) System og fremgangsmåde til aseptisk dosering
BR112013009579A2 (pt) método e comprimido
DK2627656T3 (da) Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf